| Ulaner, Gary |
MIRROR, NCT06074510: PYLARIFY® PET/CT or PET/MRI in Men with Favorable Intermediate Risk (FIR) Prostate Cancer |
|
|
| Recruiting | 4 | 274 | US | Piflufolastat F 18 Intravenous Solution [PYLARIFY], PYLARIFY, 18F-DCFPyL | Lantheus Medical Imaging | Prostate Cancer | 11/26 | 11/26 | | |
| Recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide | RayzeBio, Inc., RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 12/25 | 07/28 | | |
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
|
|
| Recruiting | 2/3 | 60 | US | FPI-2265, Ac225-PSMA I&T | Fusion Pharmaceuticals Inc. | Metastatic Castration-resistant Prostate Cancer | 07/26 | 01/31 | | |
|
NCT04700332: PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer |
|
|
| Recruiting | 2 | 184 | US | DCFPyL PET/CT | Hoag Memorial Hospital Presbyterian | Prostate Cancer | 07/22 | 12/22 | | |
NCT04883814: 18F-fluoroestradiol (FES) PET/CT for Breast Cancer |
|
|
| Active, not recruiting | 2 | 124 | US | 18F-fluoroestradiol PET/CT, FES PET/CT | Hoag Memorial Hospital Presbyterian | Breast Cancer | 12/23 | 12/23 | | |
| Active, not recruiting | 2 | 30 | US | Gallium-68 DOTATATE, Copper-64 DOTATATE | Hoag Memorial Hospital Presbyterian, RayzeBio, Inc. | Breast Cancer Stage IV | 07/24 | 07/24 | | |
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours |
|
|
| Recruiting | 1 | 110 | Canada, US | FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068 | Fusion Pharmaceuticals Inc., AstraZeneca | Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | 12/26 | 12/27 | | |
NCT06736054: A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer |
|
|
| Recruiting | 1 | 8 | US | Copper 61-PSMA PET/CT | Hoag Memorial Hospital Presbyterian | Prostate Adenocarcinoma | 03/25 | 03/25 | | |
| Recruiting | 1 | 60 | US | 89Zr-ss-pertuzumab PET/CT | Memorial Sloan Kettering Cancer Center, National Institutes of Health (NIH) | HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer | 11/26 | 11/26 | | |
NCT06736418: Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy |
|
|
| Recruiting | 1 | 65 | US | 225Ac-ABD147 | Abdera Therapeutics Inc. | Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung | 08/26 | 01/27 | | |
| Berenji, Gholam |
NCT06706921: 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer |
|
|
| Recruiting | 4 | 15 | US | 18F-Fluciclovine PET/CT Scan | VA Greater Los Angeles Healthcare System | Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male | 11/27 | 11/27 | | |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
|
|
| Recruiting | 2/3 | 60 | US | FPI-2265, Ac225-PSMA I&T | Fusion Pharmaceuticals Inc. | Metastatic Castration-resistant Prostate Cancer | 07/26 | 01/31 | | |
|
| Completed | 2 | 250 | US | 18F-DCFPyL | VA Greater Los Angeles Healthcare System | Prostate Cancer | 08/21 | 08/21 | | |
| Saboury, Babak |
NCT06736418: Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy |
|
|
| Recruiting | 1 | 65 | US | 225Ac-ABD147 | Abdera Therapeutics Inc. | Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung | 08/26 | 01/27 | | |
